The research group has previously shown that the QKI gene is a possible contributing cause of schizophrenia. Now the scientists have found that QKI normally regulates the myelin genes, that is, the genes that govern the production of myelin, the insulation material for nerve fibers. Moreover, they can show that the genetic expression of QKI is altered in schizophrenic patients and that the change correlates directly with the change in the myelin gene expression.
"In schizophrenics, fewer myelin proteins and less myelin are produced, we believe. Since myelin functions as an insulating substance around nerve fibers, impulse transmission is hampered in schizophrenics," explains Elena Jazin, one of the researchers at Uppsala University.
The team of scientists has also seen that a variant of QKI called 7kb is the variant that changes most in schizophrenic patients. This 7kb also has a major effect on the expression of myelin genes in these patients.
It is hoped that the new findings will lead to improved treatment of schizophrenia in the future. "We hope that existing drugs can be altered so that more patients will be helped and the side effects reduced. Perhaps the findings will also lead to new medicines. But this will require research and will take a long time," explains Jazin.
The research team consists of Elena Jazin, Karolina Åberg and Peter Saetre from the Uppsala University. Niclas Jareborg from Astrazeneca has also participated.
The findings were published in the online edition of PNAS (Proceedings of the National Academy of Sciences) in mid-April.
"In schizophrenics, fewer myelin proteins and less myelin are produced, we believe. Since myelin functions as an insulating substance around nerve fibers, impulse transmission is hampered in schizophrenics," explains Elena Jazin, one of the researchers at Uppsala University.
The team of scientists has also seen that a variant of QKI called 7kb is the variant that changes most in schizophrenic patients. This 7kb also has a major effect on the expression of myelin genes in these patients.
It is hoped that the new findings will lead to improved treatment of schizophrenia in the future. "We hope that existing drugs can be altered so that more patients will be helped and the side effects reduced. Perhaps the findings will also lead to new medicines. But this will require research and will take a long time," explains Jazin.
The research team consists of Elena Jazin, Karolina Åberg and Peter Saetre from the Uppsala University. Niclas Jareborg from Astrazeneca has also participated.
The findings were published in the online edition of PNAS (Proceedings of the National Academy of Sciences) in mid-April.
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"Kovalent AB´s intention is to be the most support-intensive distributor of laboratory equipment in Scandinavia." 
"We are entirely devoted to luminescence technology." 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"Our mission is to become a natural partner in storage of valuable samples." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"To support research within diabetes and cardiovascular diseases with first class unique diagnostic tests" 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala Life Science." 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"Dilafor was founded by 12 experts, which operate in Dilafor within their field of expertise, complemented by purchasing services." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"We turn medical research into applications for better health and well-being." 
"Innovation for people. We design and develop devices for the end-user." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"Novel products for CVD treatment and prevention." 
"To be acknowledged as the best in class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"Karolinska Development aims to create value by developing innovations from world class research into products that can be exited with high returns." 
